AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
Read More
Section: Regulatory
Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease
Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD
Read More
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
Read More
Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus
Therapies like topical steroids manage symptoms but there is currently no cure
Read More
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Read More